How Low Dose Lithium Affects Kidneys: What Research Shows

Updated on December 4, 2025, with new Latin American Spanish and Mandarin audio versions to help readers worldwide access this content.

🎧 ▶️ Press the play button below to listen in English.

🇪🇸 Spanish (Latinoamérica)

En este audio descubrirás cómo el litio en dosis bajas puede influir en la salud de tus riñones, según lo que muestra la investigación moderna.

Presiona el botón de reproducir para escuchar.

🇨🇳 中文（简体）

在这段音频中，你将了解最新研究显示的低剂量锂对肾脏健康的真实影响。

请按下方的播放按钮收听。

I. Introduction

Lithium has been used for decades as a treatment for bipolar disorder, but in recent years, scientists have started to look at it in a new way. Research suggests that lithium—even at very low doses—may have benefits for brain health, memory, and possibly even longevity. This has led many people to ask whether tiny amounts of lithium, often found in supplements, could be taken safely outside of traditional psychiatric use.

One of the biggest concerns with lithium is how it affects the kidneys. Since the drug is cleared entirely through the kidneys, doctors have always watched this organ closely in patients taking it. High doses over many years can sometimes lead to kidney problems, so it’s natural to wonder: Does low-dose lithium carry the same risks?

This article will explain what’s known about the safety of low-dose lithium, focusing on its effects on kidney health. We’ll look at why kidney function is so important, how lithium interacts with it, and what scientific studies tell us about long-term safety at lower doses.

---

II. Why Kidney Safety Matters

The kidneys are essential for life. They filter out toxins, balance fluids, and regulate electrolytes like sodium and potassium. Because lithium is excreted almost entirely through the kidneys, these organs are on the “front line” when it comes to lithium’s effects.

At higher doses—such as those used to treat mood disorders—lithium can cause measurable changes in kidney function. These may include:

• Polyuria and polydipsia: excessive urination and thirst, often due to lithium’s effect on the kidney’s ability to concentrate urine.
• Nephrogenic diabetes insipidus: a condition where the kidneys cannot properly respond to antidiuretic hormone, leading to persistent thirst and large urine volumes.
• Reduced glomerular filtration rate (GFR): a decline in the kidney’s ability to filter blood, which in some patients may progress to chronic kidney disease (CKD).
• Rare progression to renal failure: a small percentage of long-term high-dose users (0.5–1%) eventually develop severe kidney impairment.

An important point is that some kidney problems caused by therapeutic doses of lithium may be irreversible even if the drug is discontinued. While mild concentrating defects sometimes improve after stopping lithium, more advanced damage to the filtering units (glomeruli) often does not fully recover. This is why careful monitoring is essential for anyone taking lithium long-term.

Because of these risks, lithium users are routinely monitored with blood tests for kidney function. Even small changes in creatinine or GFR are taken seriously. For people considering low-dose lithium as a supplement, understanding these potential kidney effects is essential. The good news is that recent studies have looked explicitly at low-dose lithium and its impact on kidney health, giving us clearer answers.

III. Lithium in Mood Disorders: Typical Dosing and Risks

Lithium has been the gold standard for treating bipolar disorder for more than half a century. In this setting, it is prescribed at therapeutic doses that achieve serum levels of 0.6–1.2 mmol/L. To reach this range, patients usually take between 900 and 1,800 mg of lithium carbonate per day, divided into two or three doses.

Because mood disorders often require lifelong management, many people remain on lithium for decades. This extended exposure is where the main concerns about kidney safety come in. Research shows that:

• Mild kidney changes are common. Up to half of long-term lithium users develop some reduction in urine concentrating ability, leading to frequent urination and thirst.
• Chronic kidney disease (CKD) is possible. Between 20% and 55% of patients on long-term therapeutic doses develop stage 3 CKD (eGFR below 60 mL/min/1.73 m²).
• Renal failure is rare but real. Around 0.5–1% progress to end-stage renal disease requiring dialysis or transplant.
• Risk factors include: higher serum lithium levels (>1.0 mmol/L), longer duration of treatment, older age, and coexisting conditions like hypertension or diabetes.

For these reasons, psychiatrists routinely order creatinine and eGFR tests every 3–6 months, along with thyroid monitoring, since lithium can also affect the thyroid gland.

This background is important: it shows that while lithium is very effective for mood stabilization, long-term use at therapeutic doses carries a measurable kidney risk. This makes the safety question for low-dose lithium—much smaller amounts than used in psychiatry—even more relevant.

IV. Low-Dose Lithium: Safety Studies

As concerns about kidney health emerged with long-term, high-dose lithium, researchers began testing whether much lower doses could deliver benefits without the same risks. Several controlled studies have now examined the safety of lithium at sub-therapeutic levels, especially in older adults.

A. Aprahamian et al., 2014 (Journal of Clinical Psychiatry)

• Population: 61 elderly patients with mild cognitive impairment.
• Dose/Target: Started at 150 mg/day lithium carbonate, titrated to reach serum levels of 0.25–0.5 mmol/L.
• Duration: 2 years, double-blind, extended to 4 years total.
• Outcome: No significant decline in kidney function (measured by aMDRD and CKD-EPI equations). Some increases in thyroid-stimulating hormone (TSH) levels, weight gain, and a higher incidence of diabetes and arrhythmia were observed, but renal function remained stable.

B. Forlenza et al., 2011 & 2019 (British Journal of Psychiatry)

• Population: Older adults with amnestic mild cognitive impairment.
• Dose/Target: Lithium carbonate 150–600 mg/day, targeting 0.25–0.5 mmol/L.
• Duration: 12 to 36 months.
• Outcome: Showed signs of cognitive stabilization and biomarker improvement related to Alzheimer’s risk. Importantly, no evidence of renal impairment was reported in these trials.

C. Hampel et al., 2009 (Journal of Clinical Psychiatry)

• Population: Patients with Alzheimer’s disease.
• Duration: 10 weeks.
• Dose: Lithium carbonate, titrated toward therapeutic levels, but given only for a short term.
• Outcome: More gastrointestinal side effects on lithium, but no kidney safety signal observed during the brief trial.

D. Observational Cohorts and Reviews

• Large population studies show that renal risk rises mainly when serum lithium levels exceed 1.0 mmol/L and with long-term use.
• Patients maintained at lower serum concentrations appear less likely to develop chronic kidney disease.
• A 2023 meta-analysis confirmed that while kidney monitoring is essential, the greatest danger comes from higher doses, longer durations, and older age, rather than from cautious low-dose use.

Key takeaway: Across multiple studies, low-dose lithium (0.25–0.5 mmol/L serum)—much lower than standard psychiatric therapy—has not been linked to kidney damage over follow-ups lasting up to four years.

V. Comparing Low-Dose Lithium to Supplements

The clinical studies on low-dose lithium used lithium carbonate in doses ranging from 150 to 600 mg per day, adjusted to keep blood levels between 0.25–0.5 mmol/L. This is much lower than the therapeutic range for bipolar disorder (0.6–1.2 mmol/L), but still far higher than what is found in over-the-counter supplements.

For example:

• Lithium carbonate in low-dose trials:
  • 150–600 mg/day
  • Serum levels: 0.25–0.5 mmol/L
  • Duration studied: up to 4 years
  • Result: No decline in kidney function
• Lithium carbonate in psychiatric use:
  • 900–1800 mg/day
  • Serum levels: 0.6–1.2 mmol/L
  • Duration: often decades
  • Result: Increased risk of kidney impairment with long-term use
• Lithium orotate supplements (common form sold online):
  • Usually 1–10 mg of elemental lithium per capsule
  • At the high end (10 mg/day), this is about 30–60 times lower than the starting dose in the low-dose trials
  • Blood levels from supplement use are generally too low to register in the range measured in the medical studies

This means that people taking 5 mg of lithium orotate are consuming an amount of lithium far below what was tested in clinical trials.

If 150 mg/day lithium carbonate for 4 years did not damage the kidneys in elderly adults. In that case, it is reasonable to expect that supplement-level doses are very unlikely to cause kidney problems.

That said, lithium is still biologically active, even at small doses. Because kidneys are the main organ clearing it, it’s wise to be cautious—especially in people with existing kidney disease, hypertension, or diabetes, who already have higher kidney risks.

VI. Precautions for Supplement Users

Even though supplement doses of lithium (like 1–5 mg of lithium orotate) are far lower than the amounts used in clinical trials, it’s important to remember that lithium is still a biologically active mineral. Taking it safely requires some common-sense precautions.

1. Talk to Your Doctor First

Before starting lithium—at any dose—it’s best to consult a healthcare provider. People with kidney disease, high blood pressure, or diabetes are at higher risk for kidney problems and may need closer monitoring. Certain medications (like diuretics, ACE inhibitors, and NSAIDs) can also raise lithium levels unexpectedly.

2. Get Baseline Kidney Tests

A simple blood test for creatinine and estimated glomerular filtration rate (eGFR) gives a snapshot of kidney function. Having a baseline result allows your doctor to see if anything changes over time.

3. Monitor Periodically

If you choose to take lithium long-term—even at supplement doses—ask your doctor about repeating kidney and thyroid tests every 6–12 months. This is the same kind of monitoring used for patients on therapeutic doses, though the risk is expected to be much lower at supplement levels.

4. Stay Hydrated

Lithium is cleared through the kidneys, and dehydration can increase its concentration in the blood. Make sure to drink adequate fluids, especially during exercise or in hot weather.

5. Watch for Warning Signs

Symptoms like excessive thirst, frequent urination, tremors, or unexplained fatigue should be discussed with a healthcare provider, even if you’re only taking small doses.

---

⚠️ Key Point:
While clinical studies show that low-dose lithium (150–600 mg/day) does not damage the kidneys over several years, supplement users should still be cautious. A little vigilance goes a long way toward ensuring safety.

VII. Conclusion

Lithium has a complicated reputation. At full psychiatric doses, it is one of the most effective mood stabilizers ever discovered—but it also carries a risk of kidney problems when taken long term. These changes can sometimes be irreversible, even if lithium is stopped.

The reassuring news is that studies using low-dose lithium (150–600 mg/day, serum 0.25–0.5 mmol/L) in older adults have found no evidence of kidney decline over several years of use. This suggests that lithium can be safe when kept at lower blood levels.

For people taking supplement doses—like 1 to 5 mg of lithium orotate—the exposure is far below what was tested in these clinical trials. While the kidney risk is expected to be very small at these levels, there is not yet direct research at supplement doses. That’s why it is still important to:

• Talk to your doctor first before starting lithium.
• Get baseline and follow-up kidney tests if you plan to take it long-term.
• Stay hydrated and avoid drug interactions that can raise lithium levels.

Lithium remains a promising compound for brain health and longevity research, but like any active mineral, it must be approached with care. With medical guidance and simple monitoring, low-dose lithium can likely be used safely—without putting your kidneys at risk.

Don’t Get Sick!

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), and Telegram.

Related:

1. Lithium Controls Inflammation: Protecting Mood, Brain And Body Health
2. Lithium’s Hidden Power: Unlocking Protection Against Cardiovascular Disease
3. Lithium Sparks New Hope In Battle Against Alzheimer’s Memory Loss
4. Lithium: How This Simple Mineral Shapes the Brain and Protects Against Suicide
5. The Amazing Lithium for COVID-19 and Long COVID
6. Rethinking SSRIs and the Serotonin Theory of Depression
7. Physical Activity Prolongs Life
8. Stunning Low Doses Of Lithium Really Improve Survival
9. Your Calf Muscles Could Predict Your Lifespan
10. Blue Spaces, Longer Lives: Unlock Nature’s Hidden Advantage
11. Low Testosterone, Higher Mortality: What Two Major Studies Reveal About Hormone Health and How to Boost It Naturally

References:

1. Aprahamian, Ivan, et al. “Long-Term, Low-Dose Lithium Treatment Does Not Impair Renal Function in the Elderly: A 2-Year Randomized, Placebo-Controlled Trial Followed by Single-Blind Extension.” The Journal of Clinical Psychiatry, vol. 75, no. 7, 2014, pp. e672–e678. PubMed, https://pubmed.ncbi.nlm.nih.gov/25093483/. PubMed
2. Forlenza, Orestes V., et al. “Disease-Modifying Properties of Long-Term Lithium Treatment for Amnestic Mild Cognitive Impairment: Randomised Controlled Trial.” The British Journal of Psychiatry, vol. 198, no. 5, 2011, pp. 351–356. PubMed, https://pubmed.ncbi.nlm.nih.gov/21525519/. (Low-serum 0.25–0.5 mmol/L; safety/tolerability described.) PubMed
3. Forlenza, Orestes V., et al. “Clinical and Biological Effects of Long-Term Lithium Treatment in Older Adults with Amnestic Mild Cognitive Impairment: Randomised Clinical Trial.” The British Journal of Psychiatry, vol. 215, no. 5, 2019, pp. 668–674. Cambridge Core, https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S000712501900076X. (Low-serum 0.25–0.5 mmol/L; trial details and safety context.) Cambridge University Press & Assessment
4. Hampel, Harald, et al. “Lithium Trial in Alzheimer’s Disease: A Randomized, Single-Blind, Placebo-Controlled, Multicenter 10-Week Study.” The Journal of Clinical Psychiatry, vol. 70, no. 6, 2009, pp. 922–931. PDF, https://www.klinikum.uni-heidelberg.de/fileadmin/gerontopsychiatrie/pdf/2009_Hampel_Lithium_trial_in_AD.pdf. (Short duration; no renal signal reported.) klinikum.uni-heidelberg.de
5. Bosi, Angela T., et al. “Risk of Kidney Outcomes Associated With Lithium vs Other Mood Stabilizers in Patients With Bipolar Disorder.” JAMA Network Open, vol. 6, no. 6, 2023, e2318763. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807058. (Higher risk at >1.0 mmol/L; supports staying ≤1.0 mmol/L.) JAMA Network
6. Clos, Susana, et al. “Long-Term Effect of Lithium Maintenance Therapy on Renal Function in Patients with Bipolar Disorder: A Retrospective Cohort Study.” The Lancet Psychiatry, vol. 2, no. 12, 2015, pp. 1075–1083. https://www.sciencedirect.com/science/article/abs/pii/S2215036615003168. (Stable maintenance not linked to excess risk.) ScienceDirect
7. Gupta, Sumeet, et al. “Drug Information Update: Lithium and Chronic Kidney Disease.” BJPsych Bulletin, vol. 41, no. 6, 2017, pp. 331–334. https://pmc.ncbi.nlm.nih.gov/articles/PMC5537577/. (Notes lower therapeutic levels may spare renal function.) PMC
8. Gitlin, Michael. “Key Questions on the Long-Term Renal Effects of Lithium: A Review of the Current Literature.” International Journal of Bipolar Disorders, vol. 11, 2023, Article 37. https://journalbipolardisorders.springeropen.com/articles/10.1186/s40345-023-00316-5. (Summarizes risk factors; emphasizes dose/level and duration.) SpringerOpen
9. Van Alphen, Astrid M., et al. “Chronic Kidney Disease in Lithium-Treated Patients, Incidence and Rate of Decline.” BMC Nephrology, vol. 22, 2021, Article 15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7779378/. (General lithium CKD risk, contextual to level/duration.) PMC
10. Schoretsanitis, Georgios, et al. “Prevalence of Impaired Kidney Function in Patients With Long-Term Lithium Treatment: A Systematic Review and Meta-Analysis.” Bipolar Disorders, vol. 24, no. 8, 2022, pp. 813–826. https://pubmed.ncbi.nlm.nih.gov/34783413/. (Heterogeneous; highlights duration/levels.) PubMed
11. Strawbridge, R., et al. “Lithium: How Low Can You Go?” International Journal of Bipolar Disorders, 2024. https://journalbipolardisorders.springeropen.com/articles/10.1186/s40345-024-00325-y. (Narrative review advocating lower targets to mitigate renal risk.) SpringerOpen

Image credit: – kidney anatomy-By Piotr Michał Jaworski; PioM EN DE PL – Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=4484833

© 2018 – 2025 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases